BMO Capital Markets reissued their buy rating on shares of Boston Scientific Corporation (NYSE:BSX) in a research report report published on Friday morning. The firm currently has a $30.00 price objective on the medical equipment provider’s stock.

Several other research analysts also recently issued reports on the company. Needham & Company LLC reaffirmed a buy rating and set a $32.00 price target on shares of Boston Scientific Corporation in a research note on Tuesday, October 3rd. SunTrust Banks, Inc. reaffirmed a buy rating and set a $34.00 price target on shares of Boston Scientific Corporation in a research note on Monday, October 2nd. Stifel Nicolaus reaffirmed a buy rating and set a $32.00 price target on shares of Boston Scientific Corporation in a research note on Monday, September 25th. Jefferies Group LLC reaffirmed a hold rating on shares of Boston Scientific Corporation in a research note on Thursday, September 7th. Finally, Royal Bank Of Canada reaffirmed a buy rating and set a $31.00 price target on shares of Boston Scientific Corporation in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $30.13.

Shares of Boston Scientific Corporation (BSX) opened at 29.16 on Friday. The stock has a 50 day moving average of $28.71 and a 200-day moving average of $27.21. The firm has a market capitalization of $40.01 billion, a PE ratio of 52.16 and a beta of 1.09. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $29.54.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.27 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/boston-scientific-corporations-bsx-buy-rating-reiterated-at-bmo-capital-markets/1635388.html.

In other news, EVP Supratim Bose sold 347,137 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total transaction of $10,108,629.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP John Bradley Sorenson sold 2,100 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $27.15, for a total transaction of $57,015.00. Following the transaction, the senior vice president now directly owns 18,880 shares of the company’s stock, valued at approximately $512,592. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 531,297 shares of company stock valued at $15,144,095. Corporate insiders own 0.74% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BSX. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Boston Scientific Corporation during the 1st quarter valued at about $215,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Boston Scientific Corporation during the 1st quarter valued at about $231,000. Teachers Advisors LLC increased its stake in shares of Boston Scientific Corporation by 2.8% during the 1st quarter. Teachers Advisors LLC now owns 6,144,846 shares of the medical equipment provider’s stock valued at $152,822,000 after acquiring an additional 169,010 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Boston Scientific Corporation by 11.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 64,507 shares of the medical equipment provider’s stock valued at $1,604,000 after acquiring an additional 6,767 shares during the last quarter. Finally, Sentry Investment Management LLC increased its stake in shares of Boston Scientific Corporation by 0.9% during the 1st quarter. Sentry Investment Management LLC now owns 106,118 shares of the medical equipment provider’s stock valued at $2,639,000 after acquiring an additional 903 shares during the last quarter. 90.30% of the stock is owned by institutional investors.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.